Topical Anti-TNFα Agent Licaminlimab (OCS-02) Relieves Persistent Ocular Discomfort in Severe Dry Eye Disease: A Randomized Phase II Study

PURPOSE: To assess the efficacy, safety, and pharmacokinetics of new topical ocular anti-TNFα antibody fragment licaminlimab in the relief of persistent ocular discomfort in severe dry eye disease (DED). PATIENTS AND METHODS: Patients with ≥6-month history of DED, regular use of artificial tears, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Shettle, Lee, McLaurin, Eugene, Martel, Joseph, Seaman, John W, Weissgerber, Georges
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271287/
https://www.ncbi.nlm.nih.gov/pubmed/35821785
http://dx.doi.org/10.2147/OPTH.S366836

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271287/
https://www.ncbi.nlm.nih.gov/pubmed/35821785
http://dx.doi.org/10.2147/OPTH.S366836

Ejemplares similares